Skull Base Chordomas and Chondrosarcomas

Introduction: Chordoma vs Chondrosarcoma - Tale of Two Tumors

⭐ Chordomas are slow-growing malignant tumors from embryonic notochordal remnants, most common in clivus/sacrum, typically midline.

Clinical Presentation & Diagnosis: Skull Base Tumors - Unmasking the Culprits

• Clinical Presentation: Insidious onset; symptoms location-dependent.
  • Cranial Nerve (CN) Palsies: Most frequent.
    • Diplopia (CN VI), facial pain/numbness (CN V), hoarseness (CN IX, X). 📌 VI for VIsion double.
  • Headache: Persistent, deep-seated.
  • Nasal Symptoms: Obstruction, epistaxis (with anterior extension).
  • Brainstem Signs (late): Ataxia, motor deficits.
• Diagnosis:
  • Neuroimaging:
    • MRI:
      • Chordoma: Midline (clivus), destructive, T2 hyperintense, avid enhancement.
      • Chondrosarcoma: Off-midline (petroclival), T2 hyperintense, "rings & arcs" calcification (CT better for Ca++).
    • CT Scan: Details bony erosion, calcifications.
  • Biopsy & Histopathology: Essential for confirmation.
    • Chordoma: Physaliphorous cells (bubbly cytoplasm).
    • Chondrosarcoma: Malignant chondrocytes in cartilaginous matrix.

⭐ MRI is the gold standard for diagnosis and delineating tumor extent, especially its relationship with neurovascular structures.

Histopathology & Molecular Markers: Tumor Signatures - Cellular Clues

⭐ Brachyury (TBXT) nuclear staining is a highly specific and sensitive marker for chordoma, crucial for differentiating it from chondrosarcoma.

• Chordoma variants: Conventional, chondroid (S100+, CK+, Brachyury+), dedifferentiated.
• Chondrosarcoma grading (Evans): Grade I, II, III based on cellularity, atypia, mitotic activity.

Management & Prognosis: Skull Base Lesions - Battling the Base

• Goal: Maximal safe resection & adjuvant radiotherapy (RT).
• Surgical Approaches:
  • Endoscopic Endonasal Approach (EEA): Preferred for midline lesions (clivus, sella).
    • 
  • Open craniotomy: For lateral/complex extensions.
• Radiotherapy: Crucial for local control.
  • Proton Beam Therapy (PBT): Preferred for chordomas due to Bragg peak precision, minimizing dose to surrounding critical structures. Dose: ~70-80 GyE.
  • Photon RT (IMRT/Stereotactic): For chondrosarcomas or when PBT unavailable.

• Prognosis:
  • Chordomas: Locally aggressive, high recurrence. 5-yr survival ~50-70%.
  • Chondrosarcomas: More indolent, better prognosis. 5-yr survival ~80-90%.
  • Negative factors: Large size, brainstem involvement, incomplete resection, RT delays.

⭐ For skull base chordomas, maximal safe surgical resection followed by high-dose adjuvant radiotherapy (preferably proton beam therapy) is the standard of care and offers the best local control.

📌 Chordoma = Clivus common, Challenging, Consider PBT. Chondrosarcoma = Cartilaginous, Comparatively better prognosis.

High‑Yield Points - ⚡ Biggest Takeaways

• Chordomas: Notochord remnants, midline (clivus). Chondrosarcomas: Cartilage origin, often off-midline (petroclival).
• Symptoms: Cranial nerve palsies (esp. VI nerve), headaches.
• Chordomas: Physaliphorous cells; midline destructive, T2 hyperintense on MRI.
• Chondrosarcomas: Malignant chondrocytes; may show chondroid matrix calcification (rings/arcs).
• Treatment: Maximal safe resection + adjuvant radiotherapy (proton beam for chordomas).
• Chondrosarcomas have better prognosis; Chordomas show high local recurrence.